Annual report
2370.TEDINET S100SI7J
Period2022-10-01 → 2023-09-30
Filed2023-12-21
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 83
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥662m | 2022-10-01 → 2023-09-30 | Standalone | Net sales |
| Revenue | ¥634m | 2021-10-01 → 2022-09-30 | Standalone | Net sales |
| Revenue | ¥683m | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥783m | 2019-10-01 → 2020-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.1bn | 2018-10-01 → 2019-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.4bn | 2022-10-01 → 2023-09-30 | Standalone | Operating income |
| Operating income | −¥1.3bn | 2021-10-01 → 2022-09-30 | Standalone | Operating income |
| Ordinary income | −¥1.4bn | 2022-10-01 → 2023-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2021-10-01 → 2022-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥871m | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥837m | 2019-10-01 → 2020-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥995m | 2018-10-01 → 2019-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.4bn | 2022-10-01 → 2023-09-30 | Standalone | Income before income taxes |
| Profit before tax | −¥1.2bn | 2021-10-01 → 2022-09-30 | Standalone | Income before income taxes |
| Net income | −¥1.4bn | 2022-10-01 → 2023-09-30 | Standalone | Profit loss |
| Net income | −¥1.3bn | 2021-10-01 → 2022-09-30 | Standalone | Profit loss |
| Net income | −¥843m | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | −¥842m | 2019-10-01 → 2020-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | −¥795m | 2018-10-01 → 2019-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.6bn | at 2023-09-30 | Standalone | Assets |
| Total assets | ¥6.1bn | at 2022-09-30 | Standalone | Assets |
| Total assets | ¥5.4bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.2bn | at 2020-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.1bn | at 2019-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥590m | at 2023-09-30 | Standalone | Liabilities |
| Total liabilities | ¥566m | at 2022-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥5.0bn | at 2023-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.5bn | at 2022-09-30 | Standalone | Net assets |
| Net assets / equity | ¥4.9bn | at 2021-09-30d | Standalone | Net assets |
| Net assets / equity | ¥4.8bn | at 2020-09-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥2.6bn | at 2019-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.4bn | at 2023-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.5bn | at 2022-09-30 | Standalone | Cash and deposits |
| Cash & equivalents | ¥4.4bn | at 2023-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2022-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2021-09-30d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥3.6bn | at 2020-09-30d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.4bn | at 2019-09-30d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.3bn | 2022-10-01 → 2023-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2021-10-01 → 2022-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥975m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥633m | 2019-10-01 → 2020-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥938m | 2018-10-01 → 2019-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥3m | 2022-10-01 → 2023-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥20m | 2021-10-01 → 2022-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥344m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥86m | 2019-10-01 → 2020-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥50m | 2018-10-01 → 2019-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.2bn | 2022-10-01 → 2023-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.6bn | 2021-10-01 → 2022-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.8bn | 2019-10-01 → 2020-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥90m | 2018-10-01 → 2019-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-6.65 | 2022-10-01 → 2023-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.33 | 2021-10-01 → 2022-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.88 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.19 | 2019-10-01 → 2020-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.71 | 2018-10-01 → 2019-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥21.64 | at 2023-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥26.03 | at 2022-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥27.31 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥29.6 | at 2020-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥21.1 | at 2019-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 89.2% | at 2023-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2022-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.8% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2020-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.7% | at 2019-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -27.3% | 2022-10-01 → 2023-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -24.1% | 2021-10-01 → 2022-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -17.5% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -23.0% | 2019-10-01 → 2020-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -27.7% | 2018-10-01 → 2019-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 232,160,757 | at 2023-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 211,730,423 | at 2022-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 178,750,423 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 160,830,423 | at 2020-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 120,875,423 | at 2019-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 98 | at 2023-09-30 | Standalone | Number of employees |
| Employees | 96 | at 2022-09-30 | Standalone | Number of employees |
| Employees | 83 | at 2021-09-30d | Standalone | Number of employees |
| Employees | 78 | at 2020-09-30d | Standalone | Number of employees |
| Employees | 76 | at 2019-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-10-01 → 2023-09-30 | ¥6m |
| Reconciling Itemsreconciling | depreciation | 2022-10-01 → 2023-09-30 | ¥19m |
| Reconciling Itemsreconciling | segment assets | at 2023-09-30 | ¥4.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2023-09-30 | −¥583m |
| Cellular And Tissue Based Product Businessreportable segment | capex | 2022-10-01 → 2023-09-30 | ¥25m |
| Cellular And Tissue Based Product Businessreportable segment | depreciation | 2022-10-01 → 2023-09-30 | ¥28m |
| Cellular And Tissue Based Product Businessreportable segment | employees | at 2023-09-30 | 23 pure |
| Cellular And Tissue Based Product Businessreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥467,000 |
| Cellular And Tissue Based Product Businessreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥467,000 |
| Cellular And Tissue Based Product Businessreportable segment | segment assets | at 2023-09-30 | ¥169m |
| Cellular And Tissue Based Product Businessreportable segment | segment profit | 2022-10-01 → 2023-09-30 | −¥496m |
| Contracted Cell Manufacturing Businessreportable segment | capex | 2022-10-01 → 2023-09-30 | ¥30m |
| Contracted Cell Manufacturing Businessreportable segment | depreciation | 2022-10-01 → 2023-09-30 | ¥55m |
| Contracted Cell Manufacturing Businessreportable segment | employees | at 2023-09-30 | 63 pure |
| Contracted Cell Manufacturing Businessreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥661m |
| Contracted Cell Manufacturing Businessreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥661m |
| Contracted Cell Manufacturing Businessreportable segment | segment assets | at 2023-09-30 | ¥668m |
| Contracted Cell Manufacturing Businessreportable segment | segment profit | 2022-10-01 → 2023-09-30 | −¥346m |
| —segment total | capex | 2022-10-01 → 2023-09-30 | ¥55m |
| —segment total | depreciation | 2022-10-01 → 2023-09-30 | ¥84m |
| —segment total | revenue | 2022-10-01 → 2023-09-30 | ¥662m |
| —segment total | revenue external | 2022-10-01 → 2023-09-30 | ¥662m |
| —segment total | segment assets | at 2023-09-30 | ¥837m |
| —segment total | segment profit | 2022-10-01 → 2023-09-30 | −¥842m |
| Reconciling Itemsreconciling | capex | 2021-10-01 → 2022-09-30 | ¥13m |
| Reconciling Itemsreconciling | depreciation | 2021-10-01 → 2022-09-30 | ¥22m |
| Reconciling Itemsreconciling | segment assets | at 2022-09-30 | ¥5.3bn |
| Reconciling Itemsreconciling | segment profit | 2021-10-01 → 2022-09-30 | −¥518m |
| Cellular And Tissue Based Product Businessreportable segment | capex | 2021-10-01 → 2022-09-30 | ¥4m |
| Cellular And Tissue Based Product Businessreportable segment | depreciation | 2021-10-01 → 2022-09-30 | ¥28m |
| Cellular And Tissue Based Product Businessreportable segment | revenue | 2021-10-01 → 2022-09-30 | ¥221,000 |
| Cellular And Tissue Based Product Businessreportable segment | revenue external | 2021-10-01 → 2022-09-30 | ¥221,000 |
| Cellular And Tissue Based Product Businessreportable segment | segment assets | at 2022-09-30 | ¥147m |
| Cellular And Tissue Based Product Businessreportable segment | segment profit | 2021-10-01 → 2022-09-30 | −¥582m |
| Contracted Cell Manufacturing Businessreportable segment | capex | 2021-10-01 → 2022-09-30 | ¥60m |
| Contracted Cell Manufacturing Businessreportable segment | depreciation | 2021-10-01 → 2022-09-30 | ¥56m |
| Contracted Cell Manufacturing Businessreportable segment | revenue | 2021-10-01 → 2022-09-30 | ¥633m |
| Contracted Cell Manufacturing Businessreportable segment | revenue external | 2021-10-01 → 2022-09-30 | ¥633m |
| Contracted Cell Manufacturing Businessreportable segment | segment assets | at 2022-09-30 | ¥643m |
| Contracted Cell Manufacturing Businessreportable segment | segment profit | 2021-10-01 → 2022-09-30 | −¥233m |
| —segment total | capex | 2021-10-01 → 2022-09-30 | ¥64m |
| —segment total | depreciation | 2021-10-01 → 2022-09-30 | ¥84m |
| —segment total | revenue | 2021-10-01 → 2022-09-30 | ¥634m |
| —segment total | revenue external | 2021-10-01 → 2022-09-30 | ¥634m |
| —segment total | segment assets | at 2022-09-30 | ¥790m |
| —segment total | segment profit | 2021-10-01 → 2022-09-30 | −¥815m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,003
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in operating activities (5-year summary) | CurrentYearDuration_NonConsolidatedMember | -1263723000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 50318000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 86200000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 344245000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | Prior1YearDuration_NonConsolidatedMember | -20227000 | JPY |
| Net cash provided by used in investing activities (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 3267000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 90076000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 2786820000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 1082324000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 1584835000 | JPY |
| Net cash provided by used in financing activities (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 1157693000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 1403718000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 3643814000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 4095689000 | JPY |
| Cash and cash equivalents (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 4499095000 | JPY |
| Cash and cash equivalents (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 4396333000 | JPY |
| Number of employees | Prior4YearInstant_NonConsolidatedMember | 76 | |
| Number of employees | Prior3YearInstant_NonConsolidatedMember | 78 | |
| Number of employees | Prior2YearInstant_NonConsolidatedMember | 83 | |
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 96 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 98 | |
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 17 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 17 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 19 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 18 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 18 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.709 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.035 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.814 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 1.140 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.581 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 0.896 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 0.940 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.199 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.113 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.445 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 98 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 18 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 39.0 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 8.9 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 5469316 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember | 63 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember | 9 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 23 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 5 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 12 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 4 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 98 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 18 | |
| Research and development expenses research and development activities | CurrentYearDuration | 496674000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |